SCHEMBL16610054

SCHEMBL16610054

COc1ccc(C(=O)Oc2ccc(CO[Si](C)(C)C(C)(C)C)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.51
LMNA P02545 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
KMT2A Q03164 7/20 0.49
MAPT P10636 4/20 0.49
GFER P55789 1/20 0.49
PRSS1 P07477 1/20 0.46
ACR P10323 1/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
POLB P06746 1/20 0.46
FFAR1 O14842 1/20 0.45
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
TBXAS1 P24557 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18020584 0.90 PRSS1 (0.46) SMN1; SMN2KMT2AMAPTPRSS1ACR
SCHEMBL16610043 0.88 MAPT (0.55) KMT2AMAPTMEN1RAB9AALDH1A1
SCHEMBL16599389 0.88 TSHR (0.50) SMN1; SMN2CYP1A2CYP2C9CYP2C19KMT2A
SCHEMBL1313112 0.83 LOXL2 (0.51) SMN1; SMN2LMNAKMT2AMAPTMEN1
SCHEMBL11298531 0.82 SMN1; SMN2 (0.61) SMN1; SMN2LMNAKMT2AMAPTMEN1
SCHEMBL12909500 0.80 LMNA (0.44) SMN1; SMN2LMNAKMT2AMAPTMEN1
SCHEMBL16610053 0.80 MAPT (0.60) SMN1; SMN2LMNACYP1A2CYP2C9CYP2C19
SCHEMBL14016992 0.80 SMN1; SMN2 (0.58) SMN1; SMN2LMNACYP1A2CYP2C9CYP2C19
SCHEMBL18613360 0.79 KMT2A (0.49) SMN1; SMN2LMNAKMT2AMAPTMEN1
SCHEMBL28711315 0.79 ELANE (0.41) KMT2APRSS1MEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3049386-B9 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIV KOELN (DE) 2020-11-18 EP disclosed
EP-3049386-B9 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIV KOELN (DE) 2020-11-18 EP disclosed
US-10793509-B2 Compounds useful in the treatment of neoplastic diseases UNIVERSITÄT ZU KOLN (DE) 2020-10-06 US disclosed
US-10793509-B2 Compounds useful in the treatment of neoplastic diseases UNIVERSITÄT ZU KOLN (DE) 2020-10-06 US disclosed
EP-3049386-B1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIV KOELN (DE) 2020-07-22 EP disclosed
EP-3049386-B1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIV KOELN (DE) 2020-07-22 EP disclosed
US-20160237023-A1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIVERSITÄT ZU KÖLN (DE) 2016-08-18 US disclosed
US-20160237023-A1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIVERSITÄT ZU KÖLN (DE) 2016-08-18 US disclosed
WO-2015044177-A1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIVERSITÄT ZU KÖLN (DE) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160237023-A1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES APC, BRCA1, VHL SMN1; SMN2 346/4885LMNA 1720/4885CYP1A2 1848/4885
US-10793509-B2 Compounds useful in the treatment of neoplastic diseases APC, BRCA1, VHL SMN1; SMN2 346/4885LMNA 1720/4885CYP1A2 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.